ArticleLiver cancer2026
Survival Outcomes, Recurrence Patterns, and Its Corresponding Therapeutic Management after Conversion Therapy Followed by Curative Resection for Hepatocellular Carcinoma: A Real-World Study.
Article in Liver cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There remains a scarcity of research focusing on long-term survival, the administration of adjuvant therapy, and recurrence following conversion resection in patients suffering from initially unresectable hepatocellular carcinoma (uHCC). Our study aimed to provide a comprehensive understanding of clinical outcomes and recurrence after conversion resection of initially uHCC patients. Methods: We retrospectively collected historically confirmed HCC patients who had undergone curative resection after conversion therapy between November 2014 to June 2023. The primary endpoints included overall survival (OS) and overall survival after recurrence (rOS). The second endpoints included recurrence-free survival (RFS). BCLC staging system was applied to classify recurrence patterns (rBCLC). Results: A total of 419 initially uHCC patients were collected in Sun Yat-sen University Cancer Center. The median duration of follow-up was 44.3 months (95% CI, 26.4-62.3). These patients exhibited a median OS not reached and a median RFS of 16.8 months (95% CI, 11.5-22.1) after conversion resection. The achieving of CR according to mRECIST and pathological response ≥90% predicted better OS and RFS, while a decline of AFP or PIVKA-II ≥75% after conversion therapy predicted better RFS. Postoperative adjuvant therapy did not exhibit significantly improved OS or RFS compared to active surveillance before and after propensity score matching or inverse probability of treatment weighting. Subgroup analyses failed to identify any population with clear benefit from adjuvant therapy, either. Recurrence occurred in 261 (62.3%) patients at a median time of 7.2 months after resection. Median rOS for recurrent patients was 40.2 months (95% CI, 33.4-48.7). Patients with rBCLC stage 0/A exhibited significantly better rOS compared to those with rBCLC stage B/C. Across all rBCLC stages, curative treatment was identified as the optimal therapeutic strategy for achieving the best rOS. Furthermore, combination therapy did not demonstrate superior efficacy over transarterial therapy or systemic therapy alone at any recurrent disease stage. Conclusion: Patients with uHCC exhibited favorable prognosis after conversion resection. Tumor response of conversion therapy could predict clinical outcomes after conversion resection. Our data did not support the routine use of postoperative adjuvant therapy. When recurrence occurred, more intense and aggressive treatments were not supported by current evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.